Physiological Mechanisms
- Appetite regulation and food intake control
- Blood sugar regulation and insulin response
- Promoting feelings of fullness (satiety)
- Overall metabolic health support
Physician-Guided Care
Tirzepatide may help support appetite regulation, metabolic health, and meaningful weight-management goals when prescribed as part of an individualized, physician-supervised treatment plan.
MD consultation required, in person in Bayside, NY or by TeleDoc video visit (New York and Florida patients).
Dual receptor action
GIP + GLP-1
*Prescription treatment is appropriate only for patients who meet clinical criteria and should be used under the supervision of a qualified healthcare professional.
Tirzepatide is an injectable prescription medication that represents a dual-acting approach to metabolic regulation. It works by activating two naturally occurring hormone receptors in the body: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).
Response to treatment varies significantly between individuals. Medication is not a standalone fix, but rather one component of a comprehensive weight-management strategy that includes nutrition, physical activity, and lifestyle adjustments tailored by Dr. Maslavi.
Mechanism of Action
May help patients feel fuller sooner and maintain satiety longer, making it easier to adhere to reduced-calorie nutrition plans.
Clinical studies have demonstrated meaningful reductions in body weight in appropriate patient populations. Individual results vary.
Acts directly on hormone pathways involved in glucose regulation, supporting glycemic control and broader metabolic function.
Weight care is a long-term journey. Medication is integrated alongside dietary changes, exercise, and ongoing medical oversight.
Dr. Maslavi evaluates each patient individually before recommending prescription weight-management therapies. Medication is not automatically appropriate for every individual; thorough medical evaluation ensures safety and efficacy.
Discuss your health history, goals, current medications, and clinical eligibility with Dr. Maslavi.
Dr. Maslavi determines whether prescription medication is clinically appropriate for you.
Follow the prescribed regimen alongside tailored nutrition and lifestyle recommendations.
Regular check-ins to monitor progress, manage side effects, and adjust dosage as needed.
Gastrointestinal symptoms are most common, particularly during initiation or dose escalation:
Serious complications are rare but require immediate medical attention:
Tirzepatide is contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also contraindicated in anyone with a known serious hypersensitivity/allergy to tirzepatide or any of its ingredients. Tell your healthcare provider if you experience a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath.
Treatment recommendations are based on clinical appropriateness and may include FDA-approved medications when prescribed by Dr. Maslavi. When clinically appropriate and legally permissible, a physician may consider a compounded medication for an individual patient. Compounded medications are not FDA-approved and are subject to different regulatory requirements than FDA-approved drugs.
Clinical studies have shown that tirzepatide can produce substantial reductions in body weight in certain patient populations. Individual results vary based on dose, adherence, nutrition, activity, and metabolic factors. Refer to official FDA prescribing information and Eli Lilly clinical trials for detailed data.
Tirzepatide is the active pharmaceutical ingredient. Mounjaro® is a brand name for tirzepatide, FDA-approved for improving glycemic control in adults with type 2 diabetes. Different tirzepatide products carry specific FDA-approved indications. Patients should use the exact medication prescribed by their physician.
No. Eligibility depends on individual health factors, medical history, current medications, and clinical treatment goals evaluated during your medical consultation.
Results vary. While clinical trials demonstrated significant average weight reduction in specific study populations, individual outcomes cannot be guaranteed and depend on lifestyle factors and personal response.
Yes. Prescription treatment is designed to complement, not replace, a balanced nutritional plan, regular physical activity, and sustainable behavior modification.
Mounjaro® is FDA-approved to improve glycemic control in adults with type 2 diabetes. While weight reduction was observed as a benefit in clinical trials, tirzepatide formulations carry distinct FDA indications. Dr. Maslavi evaluates appropriate treatments based on your complete medical profile.
Bayside Only
Schedule an individualized consultation with Dr. Maslavi to discuss your medical history and explore personalized weight management options.
Talk With Dr. Maslavi About Your OptionsMD consultation required, in person in Bayside, NY or by TeleDoc video visit (New York and Florida patients).
Scheduling a consultation does not guarantee eligibility or a prescription. Treatment recommendations are determined following a medical evaluation.
Important Medical Disclaimer: This page is for educational purposes only and does not constitute medical advice or establish a doctor-patient relationship. Tirzepatide is a prescription medication and is not appropriate for everyone. All treatment decisions must be made in consultation with a qualified healthcare provider after a complete evaluation of your medical history, health metrics, and individual goals. Saul F. Maslavi, MD — Founder & Owner, PeptideDoc · NPI 1134137383
Medically reviewed by Saul F. Maslavi, MD · Last reviewed: October 2026
Available in person in Bayside, NY or by TeleDoc video visit for patients in New York and Florida.